Drug intelligence / Profile preview

IDM-4

Development stage: Discontinued
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

IDM-4 is an immuno-designed molecule developed as a targeted therapy for leukemia. It is described as a monoclonal antibody-specific antigen that selectively targets cancer cells by coupling with tumor cell-killing MAK cells derived from the patient's own monocytes. The drug was investigated in phase I/II clinical trials for leukemia, specifically chronic lymphocytic leukemia, but development appears to have been discontinued. Its mechanism involves targeting tumor antigens and facilitating immune-mediated destruction of malignant cells.

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on IDM-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDM-4.

Explore the full profile